tbuckley/cabot-search huggingface dataset:
Accuracy of computational pressure-fluid dynamics applied to coronary angiography to derive fractional flow reserve: FLASH FFR
Authors: Jianping Li, Yanjun Gong, Weimin Wang, Qing Yang, Bin Liu, Yuan Lu, Yawei Xu, Yunlong Huo, Tieci Yi, Jian Liu, Yongle Li, Shaopeng Xu, Lei Zhao, Ziad A Ali, Yong Huo
Journal: Cardiovascular Research (2019)

Conventional fractional flow reserve (FFR) is measured invasively using a coronary guidewire equipped with a pressure sensor. A non-invasive derived FFR would eliminate risk of coronary injury, minimize technical limitations, and potentially increase adoption. We aimed to evaluate the diagnostic performance of a computational pressure-flow dynamics derived FFR (caFFR), applied to coronary angiography, compared to invasive FFR.The FLASH FFR study was a prospective, multicentre, single-arm study conducted at six centres in China. Eligible patients had native coronary artery target lesions with visually estimated diameter stenosis of 30-90% and diagnosis of stable or unstable angina pectoris. Using computational pressure-fluid dynamics, in conjunction with thrombolysis in myocardial infarction (TIMI) frame count, applied to coronary angiography, caFFR was measured online in real-time and compared blind to conventional invasive FFR by an independent core laboratory. The primary endpoint was the agreement between caFFR and FFR, with a pre-specified performance goal of 84%. Between June and December 2018, matched caFFR and FFR measurements were performed in 328 coronary arteries. Total operational time for caFFR was 4.54 ± 1.48 min. caFFR was highly correlated to FFR (R = 0.89, P = 0.76) with a mean bias of -0.002 ± 0.049 (95% limits of agreement -0.098 to 0.093). The diagnostic performance of caFFR vs. FFR was diagnostic accuracy 95.7%, sensitivity 90.4%, specificity 98.6%, positive predictive value 97.2%, negative predictive value 95.0%, and area under the receiver operating characteristic curve of 0.979.Using wire-based FFR as the reference, caFFR has high accuracy, sensitivity, and specificity. caFFR could eliminate the need of a pressure wire, technical error and potentially increase adoption of physiological assessment of coronary artery stenosis severity.URL: http://www.chictr.org.cn Unique Identifier: ChiCTR1800019522.
STEM-27. LEVERAGING FUNCTIONAL GENETIC DEPENDENCIES IN TREATMENT-REFRACTORY GLIOBLASTOMA
Authors: Chirayu Chokshi, David Tieu, Kevin Brown, Chitra Venugopal, Laura Kuhlmann, Vladimir Ignatchenko, Amy Tong, Katherine Chan, Neil Savage, Minomi Subapanditha, Dillon McKenna, John Lazo, Thomas Kislinger, Jason Moffat, Sheila Singh
Journal: Neuro-Oncology (2019)

Abstract As the most common primary brain tumor in adults causing death, Glioblastoma (GBM) remains a therapeutic challenge. Unchanged for almost two decades, standard therapy is ineffective at preventing disease relapse with a median patient survival of &lt; 15 months. Stem cell-like subpopulations of tumor cells, known as brain tumor initiating cells (BTICs), evade standard therapy and lead to relapse. Whereas previous studies largely focus on pre-treatment primary GBM (pGBM), we conducted a panel of genome-wide CRISPR-Cas9 gene knockout screens to determine modulators of treatment resistance and de novo genetic vulnerabilities arising at disease recurrence. Using our in vitro model of conventional therapy, we identified genes modulating sensitivity and resistance to Temozolomide and/or radiation therapy in patient-derived pGBM BTICs. Genes modulating sensitivity belong to Fanconi anaemia nuclear complex, interstrand cross link repair, and regulation of stem cell maintenance and differentiation. Following in vitro validation of gene knockouts conferring treatment sensitization in multiple pGBM BTIC lines, we continued to conduct the first genome-wide CRISPR-Cas9 screens in patient-derived rGBM BTICs. Focusing on genetic vulnerabilities arising de novo at disease relapse, we introduce the context-specific role of protein tyrosine phosphatase 4A2 (PTP4A2) in rGBM. Genetic knockout or small molecule targeting of PTP4A2 leads to a context-specific vulnerability of rGBM self renewal capacity and in vivo tumorigenecity. To continue our analysis of treatment-refractory GBM and overcome intertumoral heterogeneity, we conducted genome-wide CRISPR-Cas9 gene knockout screens and whole cell proteomics on patient-matched pGBM and rGBM BTICs. With &gt;1000 differentially essential genes, combined functional genetic and proteomic analyses implicates genes involved in mRNA splicing, nucleotide metabolism, and activation of gene expression by sterol regulatory element-binding protein. Together, our functional genetic approach elucidates novel genes regulating treatment resistance and disease recurrence in GBM.
Trauma-Informed Care as a Universal Precaution
Authors: Nicole Racine, Teresa Killam, Sheri Madigan
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Monogenic and Polygenic Contributions to Atrial Fibrillation Risk
Authors: Seung Hoan Choi, Sean J. Jurgens, Lu-Chen Weng, James P. Pirruccello, Carolina Roselli, Mark Chaffin, Christina J.-Y. Lee, Amelia W. Hall, Amit V. Khera, Kathryn L. Lunetta, Steven A. Lubitz, Patrick T. Ellinor
Journal: Circulation Research (2019)

Rationale: Genome-wide association studies have identified over 100 genetic loci for atrial fibrillation (AF); recent work described an association between loss-of-function (LOF) variants in TTN and early-onset AF. Objective: We sought to determine the contribution of rare and common genetic variation to AF risk in the general population. Methods: The UK Biobank is a population-based study of 500 000 individuals including a subset with genome-wide genotyping and exome sequencing. In this case-control study, we included AF cases and controls of genetically determined white-European ancestry; analyses were performed using a logistic mixed-effects model adjusting for age, sex, the first 4 principal components of ancestry, empirical relationships, and case-control imbalance. An exome-wide, gene-based burden analysis was performed to examine the relationship between AF and rare, high-confidence LOF variants in genes with ≥10 LOF carriers. A polygenic risk score for AF was estimated using the LDpred algorithm. We then compared the contribution of AF polygenic risk score and LOF variants to AF risk. Results: The study included 1546 AF cases and 41 593 controls. In an analysis of 9099 genes with sufficient LOF variant carriers, a significant association between AF and rare LOF variants was observed in a single gene, TTN (odds ratio, 2.71, P =2.50×10 −8 ). The association with AF was more significant (odds ratio, 6.15, P =3.26×10 −14 ) when restricting to LOF variants located in exons highly expressed in cardiac tissue ( TTN LOF ). Overall, 0.44% of individuals carried TTN LOF variants, of whom 14% had AF. Among individuals in the highest 0.44% of the AF polygenic risk score only 9.3% had AF. In contrast, the AF polygenic risk score explained 4.7% of the variance in AF susceptibility, while TTN LOF variants only accounted for 0.2%. Conclusions: Both monogenic and polygenic factors contribute to AF risk in the general population. While rare TTN LOF variants confer a substantial AF penetrance, the additive effect of many common variants explains a larger proportion of genetic susceptibility to AF.
P2.17 Intersegmental Plane Identification with Single Lung Ventilation in PSN Resection
Authors: E. Peña Gomez Portugal, A. Leticia Solano Nieto, O. Pichardo Meneses, M.J. Midence Arguello, E. Sanchez Garcia Ramos, J. Carrillo Vidales, R. Najera Ramirez
Journal: Journal of Thoracic Oncology (2019)
Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) Following Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplants (HCT) Treated with Tabelecleucel on an Expanded Access Program
Authors: Susan Prockop, Ran Reshef, Donald E. Tsai, Nancy Bunin, Rolla Abu-Arja, Kris Michael Mahadeo, Wen-Kai Weng, Koen Van Besien, David Loeb, Sunita Dwivedy Nasta, Eneida R. Nemecek, Minoti Hiremath, Susan Yue, Yan Sun, Willis Navarro, Sarah Nikiforow
Journal: Blood (2019)
Oral contraceptives and breast cancer
Authors: E. Hemminki
Journal: BMJ (1996)

A review of data pooled from 54 case-control studies concluded that both current users of oral contraceptives (OCs) and recent discontinuers have a slightly elevated risk of breast cancer (odds ratios, 1.24 for current users and 1.16 for women who discontinued OC use 1-4 years earlier). It should be noted, however, that the pooling of data involved in this analysis cannot overcome methodological problems inherent in the individual studies, particularly selection bias. The risk of breast cancer in the fertile, sexually active women who use OCs may differ from that in sexually inactive or infertile nonusers. Moreover, women who consider themselves to be at personal risk of breast cancer may opt not to use the pill. The relationship of sensitivity to exogenous hormones, which leads many women to discontinue OC use, to hormone production and breast cancer risk is unknown. Other factors that may have an impact on breast cancer risk include age at starting and stopping OC use, continuity and duration of use, and reproductive history variables such as pregnancies, childbearing, and breast feeding. For example, both OC use before 20 years of age and long-term use before first pregnancy are increasingly common. The impact of current OC use patterns on breast cancer risk should be the focus of future methodologically sound case-control studies.
The Effect of Crizanlizumab Plus Standard of Care (SoC) Versus Soc Alone on Renal Function in Patients with Sickle Cell Disease and Chronic Kidney Disease: A Randomized, Multicenter, Open-Label, Phase II Study (STEADFAST)
Authors: Kenneth I. Ataga, Santosh L. Saraf, Vimal K. Derebail, Claire C. Sharpe, Adlette Inati, Jeffrey D. Lebensburger, Laurie DeBonnett, Shirong Zhang, Pablo Bartolucci
Journal: Blood (2019)
EPID-07. HEMATOLOGICAL ADVERSE EVENTS IN GLIOBLASTOMA PATIENTS TREATED WITH TEMOZOLOMIDE
Authors: Catherine Garcia, Zin Myint, Rani Jayswal, Allison Butts, Heidi Weiss, John Villano
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Temozolomide (TMZ) is the cornerstone for glioblastoma (GBM) treatment. A significant proportion of patients develops hematologic toxicities with limited investigations on outcomes and risk factors for their development. METHODS Our study combines data from the two largest group trials, RTOG 0525 and RTOG 0825, to analyze serious hematologic adverse events (HAE) associated with TMZ therapy for GBM. We analyzed frequency and outcomes of HAE during chemoradiation. RESULTS 1154 patients were evaluated with a median age of 57 years. Over 79% of patients developed HAE during the entire course of GBM treatment. During chemoradiation the most common HAE during chemoradiation was lymphopenia (41.5%), followed by thrombocytopenia (39.0%), and anemia (35.3%). Of these, 34.1% were severe (Grade 3 or 4) and 65.9% were mild (grade 1 or 2). During maintenance the most common HAE was leukopenia (50.7%), followed by neutropenia (50.4%), and lymphopenia (45.3%). MGMT methylation was not associated with HAEs. A history of HAEs during chemoradiation was a protective factor for developing HAEs during maintenance. MGMT methylated and age younger than 50 were protective factors for mortality. Patients that presented HAEs anytime during treatment had a longer overall survival and progression free survival. There was no significant difference in survival between mild or severe HAEs. CONCLUSION HAE are common during chemoradiation with TMZ for GBM, but are more commonly grade 1 or 2 per CTCAE. HAE during GBM treatment is associated with decreased progression free survival and overall survival.
Frequency and Prognostic Impact of IKZF1 and Co-Existed Gene Alterations in Childhood B-ALL in Taiwan
Authors: Hsi-Che Liu, Ying-Jung Huang, Ting-Chi Yeh, Tang-Her Jaing, Chao-Ping Yang, Shih-Hsiang Chen, Jen-Yin Hou, Tung-Huei Lin, Iou-Jih Hung, Lee-Yung Shih
Journal: Blood (2019)
Labelling of drugs.
Authors: D. Dunlop
Journal: BMJ (1966)

Labelling of DrugsSIR,-The report of the Committee on Safety of Drugs for 1965 expressed the view that it would conduce greatly to the safe use of drugs if containers of prescribed medicines were labelled with the name of the medicine unless otherwise specified by the doctor.This stimulated a considerable degree of comment in the lay press.The Committee is not alone in advocating this view.Nevertheless, many of your readers may be unaware of how widely it is already shared, and they may be interested, therefore,
Chemotherapy Effect on Fertility in Male Patients with Hodgkin and Non-Hodgkin Lymphoma
Authors: Ahmed Alaskar, Naila Shaheen, Saba Alsuhaymi, Nouf Alqahtani, Nouf Bin Muammar, Zaha Jamaan, Noura Alhmanai, Mohsen Alhazmi, Shatry Hind, May Anne Mendoza, Ayman Alhejazi, Khadega Abuelgasim, Giamal Gmati, Moussab Damlaj, Hind Salama, Mohsen Alzahrani, Bader Alahmari, Mahmoud Salam, Abin Thomas
Journal: Blood (2019)
A Multicenter Randomized Non-Inferiority Study of Homoharringtonine Versus Etoposide in Induction Phase for Chinese Childhood Acute Myeloid Leukemia - a Report from China Children's Leukemia Group (CCLG)
Authors: Jing Li, Jiaole Yu, Ruidong Zhang, Ju Gao, Changda Liang, Ansheng Liu, Wei Liu, Lijun Qu, Yufeng Liu, Hongsheng Wang, Minghua Yang, Yunpeng Dai, Hui Jiang, Yongjun Fang, Lirong SUN, Xiuli Ju, Xin Tian, Jianxin Li, Xiaodong Shi, Li Wang, Leping Zhang, Runming Jin, Yan Chen, Guoping Hao, Mei Yan, Hui Liang, Cuimin Zheng, Sen Chen, Jingrong Zhang, Haixia Cao, Kaili Pan, Qun Hu, Zhixu He, Min Zhou, Weihong Zhao, Yilin Wang, Rong Zhang, Yueqin Han, Aimin Li, Huyong Zheng
Journal: Blood (2019)
Progression of Albuminuria in Sickle Cell Anemia: A Multicenter, Longitudinal Study
Authors: Omar Niss, Adam Lane, Monika Asnani, Marianne McPherson Yee, Ashok Raj, Susan E Creary, Courtney D. Fitzhugh, Prasad V. Bodas, Santosh L. Saraf, Sharada Sarnaik, Charles T. Quinn, Prasad Devarajan, Punam Malik
Journal: Blood (2019)
Impact of Preemptive Leucovorin Dose Escalation on Incidence of Delayed Methotrexate Elimination in Lymphoma Patients Receiving High-Dose Methotrexate
Authors: Jason N Barreto, Erin F Barreto, Kristen T Peterson, Ross Dierkhising, Kristin C. Mara, Nelson Leung, Carrie A. Thompson
Journal: Blood (2019)
Maintenance of Long-Term Undetectable Minimal Residual Disease after Combination of Ibrutinib with Abbreviated Chemotherapy in the Icll-07 Filo Trial
Authors: Anne-Sophie Michallet, Marie-Sarah Dilhuydy, Fabien Subtil, Valérie Rouille, Beatrice Mahe, Kamel Laribi, Bruno Villemagne, Gilles A. Salles, Olivier Tournilhac, Alain Jacques Delmer, Christelle Portois, Brigitte Pegourie, Veronique Leblond, Cecile Tomowiak, Sophie de Guibert, Frederique Orsini, Anne Banos, Philippe Carassou, Guillaume Cartron, Luc Mathieu Fornecker, Loic Ysebaert, Caroline Dartigeas, Margot Truchan, Jean Pierre Vilque, Thérèse Aurran, Florence Cymbalista, Stephane Lepretre, Vincent Levy, Florence Nguyen-Khac, Magali Le Garff-Tavernier, Carmen Aanaei, Michel Ticchioni, Remi Letestu, Pierre Feugier
Journal: Blood (2019)
Real World Outcomes of Letermovir Prophylaxis in Unselected High Risk CMV Seropositive Hematopoietic Stem Cell Transplant Recipients
Authors: Eva Karam, Justin LaPorte, Connie Sizemore, Xu Zhang, H. Kent Holland, Melhem Solh, Lawrence E Morris, Asad Bashey, Scott R. Solomon
Journal: Blood (2019)
Hypertension and Toxaemia
Authors: J. Sophian
Journal: BMJ (1965)

MEDITALSOUHALneedle was used and the dorsum of the hand always chosen as the site of injection.With a little care this can be a relatively easy tech- nique.The results were much improved.The local anaesthetic used was prilocaine (Citanest) 0.5% without adrenaline, the aver- age dose being 30 ml. (150 mg.), decreasing to 20 ml.(100 mg.) in thin and frail limbs and increasing to 40 ml.(200 mg.) in fat and more muscular limbs.In one case a total of 60 ml.(300 mg.) had to be injected as the tourniquet accidentally deflated lN minutes after the first 40 ml.had been injected.There were no systemic effects seen in any case.The time of inflation of the tourniquet ranged from 10 minutes to 1 hour 45 minutes.-Iam, etc.,
Treatment Outcome and a Practical 10-Point Prognostic Index in Adult Patients with Non-M3 Acute Myeloid Leukemia: A Retrospective, Multicenter Study in Malaysia
Authors: Tze Shin Leong, Sen Mui Tan, Lee Ping Chew, Tee Chuan Ong, Siew Lian Chong, Kar Ying Yong, Siong Leng Hon, Syazarin Fidhora Nasution, Ching Tiong Ko, Vanusha Devaraja, Andy Sing Ong Tang, Tsen Chuen Jerome Tan, Ngee Siang Lau, Sharifah Shahnaz Syed Abd Kadir, Veena Selvaratnam, Yee Yee Yap, Bee Sun Lee, William Kian Boon Law, Jameela Sathar
Journal: Blood (2019)
Clinical Outcomes of Obinutuzumab Therapy across Non-Hodgkin Lymphoma Subtypes
Authors: Mitchell E. Hughes, Esin C. Namoglu, Connie Suen, Stephen J Schuster, Jakub Svoboda, Daniel J. Landsburg, Stefan K. Barta, James N. Gerson, Kyle Robinson, Elise A. Chong, Joanna M Rhodes, Emily C. Ayers, Alison W. Loren, Edward A. Stadtmauer, Sunita Dwivedy Nasta
Journal: Blood (2019)
Ibrutinib for relapsed/refractory mantle cell lymphoma: 7-year experience
Authors: I.T. Grilo, M.E. Couto, J.F. Freitas, D.P. Pereira, C. Moreira, S. Chacim, N. Domingues, A.E. Santo, Â Martins, L. Viterbo, I. Oliveira, I. Moreira, J.M. Mariz
Journal: Annals of Oncology (2019)
Serum Proteins in Pulmonary Tuberculosis
Authors: I. C. Gilliland, R. N. Johnston, P. Stradling, E. M. Abdel-Wahab
Journal: BMJ (1956)

MBRriTsHcase required 3-4 weeks, another 5-6, and a third 12 weeks' continuous treatment before the sputum could be rendered mucoid and H. influenzae-negative.One case failed to respond.A total of 204 relapses were observed during 306 patient-months of intermittent antibacterial treatment.The majority were associated with reappearance of H. influenzae.In our view, the conclusion is inescapable that noncapsulated H. influenzae is responsible for keeping the chronic inflammatory process smouldering in bronchi- ectatic individuals.We are indebted to the Antibiotics Clinical Trials (Non-
Mind-Body Therapies for Opioid-Treated Pain
Authors: Eric L. Garland, Carrie E. Brintz, Adam W. Hanley, Eric J. Roseen, Rachel M. Atchley, Susan A. Gaylord, Keturah R. Faurot, Joanne Yaffe, Michelle Fiander, Francis J. Keefe
Journal: JAMA Internal Medicine (2019)

Mind-body therapies (MBTs) are emerging as potential tools for addressing the opioid crisis. Knowing whether mind-body therapies may benefit patients treated with opioids for acute, procedural, and chronic pain conditions may be useful for prescribers, payers, policy makers, and patients.
Clinical Features of Post-Transplant Lymphoproliferative Disease Are Different between Kidney-Transplant Recipients from a Cadaveric Donor and Those from a Living Donor
Authors: Shoko Oshima, Akihito Shinohara, Hideki Ishida, Miki Umeda, Satoko Osanai, Satoru Itoi, Michiko Ryuzaki, Yuki Izuka, Aya Watanabe, Norina Tanaka, Midori Ishiyama, Hiroshi Kazama, Kentaro Yoshinaga, Shotaro Hagiwara, Masayuki Shiseki, Junji Tanaka
Journal: Blood (2019)
Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes
Authors: Guillermo Montalban-Bravo, Elias Jabbour, Caleb Class, Nicholas J. Short, Rashmi Kanagal-Shamanna, Tapan M. Kadia, Gautam M. Borthakur, Naveen Pemmaraju, Koji Sasaki, Zeev E. Estrov, Jorge E. Cortes, Farhad Ravandi, Yesid Alvarado, Rami S. Komrokji, Mikkael A. Sekeres, David P. Steensma, Amy E. DeZern, Gail J. Roboz, Hui Yang, Hagop M. Kantarjian, Guillermo Garcia-Manero
Journal: Blood (2019)
Bio-Inspired Functional Lipoprotein-like Nanoparticles (Flip-NPs) Cause Cholesterol Starvation and Ferroptosis in B-Cell Lymphomas: Studies in Cell Lines, Xenograft Models and Primary Patient Samples
Authors: Jonathan Rink, Adam Yuh Lin, Shuo Yang, Amir Behdad, Reem Karmali, Colby Shad Thaxton, Leo I. Gordon
Journal: Blood (2019)
Hospitalization Patterns with Commercial CAR T-Cell Therapy: A Single Institution Experience
Authors: Sunita Dwivedy Nasta, Esin C. Namoglu, Mitchell E. Hughes, Elise A. Chong, Jakub Svoboda, Hatcher J. Ballard, Daniel J. Landsburg, Meredith I LaRose, Stefan K. Barta, James N. Gerson, Marco Ruella, Noelle V. Frey, Stephen J. Schuster, David L. Porter
Journal: Blood (2019)
A New Cytokine-Based Stratification Is Highly Predictive of Survivals in AML Patients
Authors: Pierre Peterlin, Joelle Gaschet, Thierry Guillaume, Alice Garnier, Marion Eveillard, Amandine Le Bourgeois, Michel Cherel, Juliette Brouazin, Camille Debord, Yannick Le Bris, Olivier Theisen, Beatrice Mahe, Viviane Dubruille, Soraya Wuilleme, Catherine Godon, Cyrille Touzeau, Thomas Gastinne, Nicolas Blin, Anne Lok, Benoit Tessoulin, Steven Le Gouill, Philippe Moreau, Marie-Christine Béné, Patrice Chevallier
Journal: Blood (2019)
The Acute Throat
Authors: G. Sclare
Journal: BMJ (1949)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following The Acute Throat Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Risk-Adapted, Ofatumumab-Based Chemoimmunotherapy and Maintenance in Treatment-Naïve CLL: A Phase II Study
Authors: Sanjal Desai, Dennis Drinkwater, Clifton Craig Mo, Mohammed ZH Farooqui, Susan Soto, Janet Valdez, Erika M Gaglione, Xin Tian, Pia Nierman, Jennifer Lotter, Gerald Marti, Cydney Nichols, Alankrita Taneja, Sarah E. M. Herman, Irina Maric, Laura M Wake, Maryalice Stetler-Stevenson, Constance M. Yuan, Tom Hughes, Margaret A. Lindorfer, Ronald P. Taylor, Adrian Wiestner, Inhye E Ahn
Journal: Blood (2019)